Soon enough, a few cosmetics companies stepped in with skincare products and others are expected to follow
These GLP-1 receptor agonists help curb appetite by targeting hunger centers in the brain, enhance metabolic function by improving insulin sensitivity and slowing gastric emptying, and may even reduce the risk of developing type 2 diabetes by managing risk factors effectively
I think that once Mounjaro is approved for weight loss at the end of 2023 this trend will gain steam in a significant way, which would likely reflect in Q2-Q3 2024 earnings for PHG, RMD etc
Magnetic resonance studies have provided mixed results regarding GSH levels in schizophrenia patients, with some studies indicating decreased levels in chronic schizophrenia, while others found no significant differences
Maybe in the long run, say, after ten years, GLP-1s for weight loss are cost-effective or even cost-saving